Publication: Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations
Issued Date
2018-08-09
Resource Type
ISSN
14786362
14786354
14786354
Other identifier(s)
2-s2.0-85054930382
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Arthritis Research and Therapy. Vol.20, No.1 (2018)
Suggested Citation
John A. Reynolds, Eoghan M. McCarthy, Sahena Haque, Pintip Ngamjanyaporn, Jamie C. Sergeant, Elaine Lee, Eileen Lee, Stephen A. Kilfeather, Ben Parker, Ian N. Bruce Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Research and Therapy. Vol.20, No.1 (2018). doi:10.1186/s13075-018-1666-0 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45990
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations
Abstract
© 2018 The Author(s). Background: Patients with SLE display marked clinical and immunlogical heterogeneity. The purpose of the study was to investigate patterns of serum cytokines in patients with active and stable systemic lupus erythematosus (SLE) and to determine how they relate to clinical phenotype. Methods: Serum levels of 10 cytokines were measured retrospectively in a cohort of patients with SLE and in healthy controls using a high-sensitivity multiplex bead array. Disease activity was determined using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG-2004) indices. Logistic regression models were used to determine the association between cytokine levels and active SLE. Principal component analysis (PCA) and cluster analysis was then used to identify subgroups of patients on the basis of cytokine levels. Results: Serum chemokine (C-X-C motif) ligand 10 (CXCL10) and CXCL13 were significantly higher in patients with SLE compared to healthy controls. Two cytokines (pentraxin-related protein (PTX3) and CXCL10) were significantly higher in patients with active disease after adjustment for potential confounding factors. Measurement of four cytokines (CXCL10, IL-10, IL-21 and PTX3) significantly improved the performance of a model to identify patients with clinically active disease. Cluster analysis revealed that the patients formed 3 distinct groups, characterised by higher levels of interferon alpha (IFNα) and B lymphocyte stimulator (BLyS) (group 1), increased CXCL10 and CXCL13 (group 2) or low levels of cytokines (group 3). Group 2 had significantly lower serum complement and higher anti-double-stranded DNA antibodies and increased prevalence of inflammatory arthritis. Conclusions: Multiplex analysis has identified a serum cytokine signature for active SLE. Within the SLE population distinct cytokine subgroups were identified, with differing clinical and immunological phenotypes that appeared stable over time. Assessment of cytokine profiles may reveal unique insights into disease heterogeneity.